Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model

Ítems similars

• No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
  per: Viviana Laredo, et al.
  Publicat: (2020-05-01)
• No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
  per: Laredo, Viviana, et al.
  Publicat: (2020)
• Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
  per: I. N. Dyakov, et al.
  Publicat: (2020-09-01)
• Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?
  per: Biondi-Zoccai, Giuseppe, et al.
  Publicat: (2010)
• The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
  per: Choi, Woong Gil, et al.
  Publicat: (2021)